- Home
- TOVX vs ENSC Comparison
TOVX vs ENSC Comparison
Compare TOVX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- ENSC
- Stock Information
- Founded
- TOVX 2001
- ENSC 2003
- Country
- TOVX United States
- ENSC United States
- Employees
- TOVX N/A
- ENSC N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- ENSC Health Care
- Exchange
- TOVX Nasdaq
- ENSC Nasdaq
- Market Cap
- TOVX 3.6M
- ENSC 2.9M
- IPO Year
- TOVX 2006
- ENSC N/A
- Fundamental
- Price
- TOVX $0.64
- ENSC $2.08
- Analyst Decision
- TOVX Hold
- ENSC
- Analyst Count
- TOVX 1
- ENSC 0
- Target Price
- TOVX N/A
- ENSC N/A
- AVG Volume (30 Days)
- TOVX 2.4M
- ENSC 4.9M
- Earning Date
- TOVX 05-20-2025
- ENSC 05-20-2025
- Dividend Yield
- TOVX N/A
- ENSC N/A
- EPS Growth
- TOVX N/A
- ENSC N/A
- EPS
- TOVX N/A
- ENSC N/A
- Revenue
- TOVX N/A
- ENSC $5,210,031.00
- Revenue This Year
- TOVX N/A
- ENSC N/A
- Revenue Next Year
- TOVX N/A
- ENSC N/A
- P/E Ratio
- TOVX N/A
- ENSC N/A
- Revenue Growth
- TOVX N/A
- ENSC 133.58
- 52 Week Low
- TOVX $0.74
- ENSC $1.62
- 52 Week High
- TOVX $12.25
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- TOVX 23.36
- ENSC 39.27
- Support Level
- TOVX $1.32
- ENSC $2.86
- Resistance Level
- TOVX $1.45
- ENSC $3.23
- Average True Range (ATR)
- TOVX 0.14
- ENSC 0.37
- MACD
- TOVX -0.07
- ENSC -0.00
- Stochastic Oscillator
- TOVX 2.92
- ENSC 14.24
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.